EPO and myelodysplastic syndrome: In this trial, the HI-E response rate was 57.1% among patients with a baseline serum EPO ≤ 200 U/L (n = 14), which is higher than that reported for NTD patients with LR-MDS and a baseline serum EPO level of < 200 U/L (20/40 patients [50.0%]) in the phase 3 EPOANE trial [14].